Market Place
Sourcing Support
ProMIS Neurosciences Announces 2025 Results and Update
25 Mar 2026 //
GLOBENEWSWIRE
ProMIS Neurosciences Presents ALS/Parkinson`s Data at AD/PD 2026
18 Mar 2026 //
GLOBENEWSWIRE
Promis Neurosciences Presents at Guggenheim Emerging Outlook 2026
04 Feb 2026 //
GLOBENEWSWIRE
Promis Neurosciences Reveals $175M Private Placement Financing
30 Jan 2026 //
GLOBENEWSWIRE
Promis Neurosciences Surpasses Enrollment Goal In PMN310
18 Dec 2025 //
GLOBENEWSWIRE
ProMIS Peer-Reviewed Pub: Selective Targeting Reduces ARIA Risk
10 Dec 2025 //
GLOBENEWSWIRE
Promis Neurosciences Joins 8Th Evercore Healthcare Conference
01 Dec 2025 //
GLOBENEWSWIRE
Promis Neuro Reveals Plasma pTau`s Role In Alzheimer Trials
01 Dec 2025 //
GLOBENEWSWIRE
Promis Neurosciences Announces Reverse Stock Split
24 Nov 2025 //
GLOBENEWSWIRE
Promis Neuros Reveals Q3 2025 Financials & Milestones Update
12 Nov 2025 //
GLOBENEWSWIRE
Promis Neurosciences Joins Guggenheim Healthcare Innovation
03 Nov 2025 //
GLOBENEWSWIRE
Promis Neurosciences Appoints Slanix Paul Alex, Pharm.D. To Board
22 Oct 2025 //
GLOBENEWSWIRE
Promis Neurosciences Advances PMN310 in Phase 1b Alzheimer Trial
03 Sep 2025 //
GLOBENEWSWIRE
ProMIS to Present Drug Discovery Platform & PRECISE-AD Trial
29 Jul 2025 //
GLOBENEWSWIRE
ProMIS Neuro Announces $0.8M Direct Offering Under Nasdaq Rules
22 Jul 2025 //
GLOBENEWSWIRE
ProMis Neurosciences Announces Private Placement Financing
22 Jul 2025 //
GLOBENEWSWIRE
FDA Grants Fast Track Designation to ProMIS` PMN310
21 Jul 2025 //
GLOBENEWSWIRE
ProMIS Neurosciences Q1 2025 Financial Results
12 May 2025 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces 2024 Financial Results
31 Mar 2025 //
GLOBENEWSWIRE
ProMIS Neurosciences Presents Preclinical Data at 2025 Conference
24 Mar 2025 //
GLOBENEWSWIRE
ProMIS Neuroscience Presents Preclinical Data on Vaccines at Meeting
13 Mar 2025 //
GLOBENEWSWIRE
ProMIS Neurosciences at 37th Annual Roth Conference
11 Mar 2025 //
GLOBENEWSWIRE
ProMIS Neurosciences doses first patients in Phase 1b trial for AD
25 Feb 2025 //
GLOBENEWSWIRE
ProMIS Neuro to Participate in Guggenheim Cap Biotech Conference
29 Jan 2025 //
GLOBENEWSWIRE
ProMIS Neurosciences Issues Letter to Shareholders
13 Jan 2025 //
GLOBENEWSWIRE
Promis Neurosciences Starts Phase 1b Precise-Ad Alzheimer’s Trial
10 Jan 2025 //
GLOBENEWSWIRE
ProMIS Neurosciences to Attend Evercore HealthCONx Conference
26 Nov 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Reports Q3 2024 Financial Results & Updates
14 Nov 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences to Join Guggenheim Healthcare Conference
12 Nov 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Presents PMN310 Alzheimer’s Data
30 Oct 2024 //
GLOBENEWSWIRE
ProMIS To Showcase PMN310 At Cognitive & Behavioral Neurosciences Conference
12 Sep 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences To Present At H.C. Wainwright Conference
05 Sep 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Q2 2024 Results And Recent Highlights
08 Aug 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces ALS Data Publication
06 Aug 2024 //
GLOBENEWSWIRE
ProMIS To Participate In BTIG Virtual Biotechnology Conference
01 Aug 2024 //
GLOBENEWSWIRE
ProMIS Presents Novel Alzheimer`s Vaccine Approach At AAIC 2024
30 Jul 2024 //
GLOBENEWSWIRE
ProMIS Study on Amyloid-Beta Oligomer Selective Antibodies
30 Apr 2024 //
GLOBENEWSWIRE
ProMIS Neuro Achieves Milestone in Development of Alpha-Synuclein Vaccine
22 Jan 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310
20 Nov 2023 //
GLOBENEWSWIRE
Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine
25 Apr 2023 //
GLOBENEWSWIRE
ProMIS Announces Submission of IND Application for Lead Antibody PMN310
10 Apr 2023 //
GLOBENEWSWIRE
Lead Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers
29 Mar 2023 //
GLOBENEWSWIRE
ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023
13 Mar 2023 //
GLOBENEWSWIRE
